Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business HighlightsBusiness Wire • 02/19/26
Prothena to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026Business Wire • 02/12/26
Prothena Announces Poster Presentation on its TDP-43 CYTOPE® Program at Neuroscience 2025Business Wire • 11/19/25
Prothena Highlights Phase 2 Data for Coramitug (Formerly PRX004) Published in Circulation, Official Journal of AHABusiness Wire • 11/11/25
Prothena Reports Third Quarter 2025 Financial Results and Business HighlightsBusiness Wire • 11/06/25
Prothena's Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 (PRX005), an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimer's DiseaseBusiness Wire • 10/01/25
Prothena (PRTA) Up 17.6% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 09/03/25
Prothena to Participate in the Cantor Fitzgerald Global Healthcare ConferenceBusiness Wire • 08/28/25
Prothena Provides Update on PRX012 and Announces Results from the Phase 1 ASCENT Clinical ProgramBusiness Wire • 08/27/25
Prothena Announces that Novo Nordisk Will Advance Coramitug (Formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with CardiomyopathyBusiness Wire • 08/06/25
Prothena Reports Second Quarter 2025 Financial Results and Business HighlightsBusiness Wire • 08/04/25
PRTA Dives 53.5% YTD: Will the Restructuring Effort Boost Prospects?Zacks Investment Research • 07/04/25
Prothena's Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's DiseaseBusiness Wire • 06/16/25